• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ALK-Abelló

264.80 DKK

-0.53 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.53 %
+2.48 %
+18.96 %
+15.84 %
+16.24 %
+42.67 %
+223.12 %
+92.72 %
+667.54 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
59B DKK
Turnover
10.86M DKK
Revenue
6.31B
EBIT %
26.2 %
P/E
49.04
Dividend yield-%
0.6 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
20/8
2026

Interim report Q2'26

18/11
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/4/2026, 6:30 AM

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

ALK-Abelló
Regulatory press release6/1/2026, 7:20 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Press release5/29/2026, 2:27 PM

ALK to present at the Jefferies Global Healthcare Conference in New York

ALK-Abelló

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/4/2026, 10:16 AM

Three-month interim report (Q1) 2026 (unaudited)

ALK-Abelló
Regulatory press release5/4/2026, 10:08 AM

ALK upgrades its full-year outlook

ALK-Abelló
Press release4/28/2026, 2:13 PM

Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026

ALK-Abelló
Regulatory press release4/20/2026, 12:33 PM

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

ALK-Abelló
Press release4/15/2026, 10:07 AM

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK-Abelló
Regulatory press release4/8/2026, 8:37 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release4/1/2026, 8:05 AM

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK-Abelló
Press release3/31/2026, 7:01 AM

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

ALK-Abelló
Regulatory press release3/16/2026, 5:37 PM

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

ALK-Abelló
Press release3/4/2026, 10:20 AM

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

ALK-Abelló
Regulatory press release2/20/2026, 1:54 PM

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

ALK-Abelló
Regulatory press release2/20/2026, 6:31 AM

Henriette Mersebach to step down as ALK’s head of R&D

ALK-Abelló
Regulatory press release2/20/2026, 6:17 AM

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

ALK-Abelló
Press release2/13/2026, 11:16 AM

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

ALK-Abelló
Regulatory press release1/29/2026, 3:15 PM

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

ALK-Abelló
Press release1/8/2026, 4:17 PM

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

ALK-Abelló
Press release12/22/2025, 3:13 PM

ALK – Financial calendar for the 2026 financial year

ALK-Abelló